June #24 : A Higher Standard - by Walter Armstrong and Ronnilyn Pustil

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Archives » POZ Magazine issues




Table of Contents

Nowhere Else to Go

Great Escapes

Gotta Light?

The Great Sex Debate

Made in Japan

Clipped Wings

The Vinyl Solution

Into the Woods

Hazel's House

Open Windows

S.O.S.-June 1997

Mailbox-June 1997

Ad Lip

A Higher Standard

Just Not Like a Prayer

Who's Sore-y Now?

Say What-June 1997

Devil to Pay

Web of Cries

On Pins and Needles

Fatal Attraction

Cocktails for Kids

To B or Not to B

Pot Doc Stalked

Obituaries

Alexander the Great(ish)

POZ Picks-June 1997

Skin Traders

Absolutely Fabregas

Barbarians at the Gates

Borders on Madness

A Second Look

Painful Truths

Before the Revolution

Riding Bareback

The Fleecing of Oprah

Barrier Blues

Mixed and Matched

To Tell the Truth

The Borders of Health

Road Trip Grub Tips

Following Your HAART

TLC for Your Largest Organ

Art and Soul

Farewells



Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV


email print

June 1997

A Higher Standard

by Walter Armstrong and Ronnilyn Pustil

Groundbreaking guidelines for treatment of HIV

According to Project Inform’s Martin Delaney, at presstime the Public Health Service (PHS) was drafting a radical revision of the Standard of Care for HIV treatment. The PHS panel of physicians, activists and officials recommends slugging the virus with as potent a protease/nuke three-drug cocktail as possible. Merck’s Crixivan (indinavir), Abbott’s ritonavir (Norvir) and Viracept (nelfinavir), the new Agouran protease, are first choices; Roche’s saquinavir (Invirase) didn’t make the cut. No guidelines about the preferred nuke duo will be issued (in practice, d4T/3TC is gaining fast on front-runner AZT/3TC), but do expect a warning: Don’t tack a protease onto your current regimen—switch one or both nukes to combat resistance. While backing the “Hit It Hard” half of last year’s mantra, the experts backed off from endorsing “Hit It Early” for people with more than 300 CD4s unless viral load is high.

The regs, set for a summer release to physicians nationwide, mark a treatment-strategy revolution. “Enormous education of doctors is critical. That should be the PHS’s next step,” said Delaney, a panel member, adding that the report leaves unresolved the knottiest issues: Which drugs to start with, and when. “We don’t know because the trials aren’t being done. The next challenge for activists is to pressure drug companies and researchers to do these studies."



[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Poll
Have you ever been diagnosed with diabetes or pre-diabetes?
Yes
No

Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.